Viewing nowCombinationOlostan Tablet 40/20mg (Olmesartan Medoxomil, Rosuvastatin)
Rosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.

MFDS item code 201308099 · Approved 2013.07.10 · Insurance code 641605710
Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular risk
This medication is used for patients who need to take two drugs, Olmesartan Medoxomil and Rosuvastatin. Olmesartan Medoxomil helps to treat essential hypertension, which is high blood pressure with unknown cause. Rosuvastatin is used to improve hypercholesterolemia and dyslipidemia when not adequately controlled by diet and exercise. It also lowers cholesterol levels in patients at high risk for cardiovascular diseases and delays the progression of atherosclerosis, thus reducing the risk of stroke and myocardial infarction. This medication is used to improve cardiovascular health in patients with both hypertension and dyslipidemia.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil Adults: The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If further blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose with careful monitoring of their condition. Older adults: No dose adjustment is necessary when this medicine is administered to older adults 65 years of age or older. Patients with renal impairment: The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose in patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use of this medicine is not recommended in patients with severe hepatic impairment because there is no experience with its use. Rosuvastatin Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: Patients taking this medicine, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine 20mg to patients with moderate renal impairment. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
The safety and efficacy in children under 18 years of age have not been established.
This medication can cause serious harm to the fetus if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Those allergic to this medication or its components, pregnant or potentially pregnant women, breastfeeding individuals, and those with severe kidney or liver dysfunction should not take this medication. Particularly, patients undergoing dialysis or with severe renal failure, biliary obstruction, muscle diseases, or those taking certain medications should not use this medication. Patients with excessively low blood pressure or decreased blood volume, impaired kidney function, or at risk for hyperkalemia should use this drug with caution, and blood pressure, kidney function, and serum potassium levels should be monitored frequently. If symptoms such as muscle pain or weakness, or myopathy occur, consult a doctor immediately, and in severe cases, medication may need to be stopped. This medication may also affect liver function, so regular liver function tests before and during treatment are important. Additionally, this medication may interact with other drugs, so be sure to inform your doctor or pharmacist of any other medications you are taking. Elderly patients or those with specific genetic characteristics may require adjusted dosages, so caution is advised. In case of overdose, symptoms such as hypotension or cardiac arrhythmias may occur; should such symptoms appear, immediate medical attention is required. This medication should not be used in children as its safety and efficacy have not been established. Lastly, this medication should be kept out of the reach of children and should not be transferred to other containers.
elevated ALT, elevated AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal rigidity, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, asthenia, vascular edema, anaphylactic reaction, vomiting, chronic malabsorption, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute kidney failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, increased blood pressure, facial edema, low back pain, increased blood creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reaction including vascular edema, diabetes, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, shortness of breath, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it should be stored at room temperature between 1 and 30 degrees Celsius, away from extreme heat or cold.
Dark pink round film-coated tablet
30 tablets (10 tablets/PTP) × 3, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Mothers Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.